Literature DB >> 17410337

Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia.

K Govind Babu1, Venkata Satya Suresh Attili, P P Bapsy, G Anupama.   

Abstract

Imatinib is presently the commonest prescribes drug for patients of chronic myelogenous leukemia (CML) in chronic phase (CP) worldwide. Its ocular side effects are little known. Optic neuritis caused by this drug has not been reported (Medline search). We describe perhaps the first case of optic neuritis caused by this drug.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17410337     DOI： 10.1007/s10792-007-9038-9

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN： 0165-5701            Impact factor:   2.031


  3 in total

1.  High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.

Authors:  Hagop Kantarjian; Moshe Talpaz; Susan O'Brien; Guillermo Garcia-Manero; Srdan Verstovsek; Francis Giles; Mary Beth Rios; Jianqin Shan; Laurie Letvak; Deborah Thomas; Stefan Faderl; Alessandra Ferrajoli; Jorge Cortes
Journal:  Blood       Date:  2003-12-24       Impact factor: 22.113

2.  Ocular side-effects associated with imatinib mesylate (Gleevec).

Authors:  Frederick W Fraunfelder; Jonathan Solomon; Brian J Druker; Bita Esmaeli; Jennifer Kuyl
Journal:  J Ocul Pharmacol Ther       Date:  2003-08       Impact factor: 2.671

3.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Stephen G O'Brien; François Guilhot; Richard A Larson; Insa Gathmann; Michele Baccarani; Francisco Cervantes; Jan J Cornelissen; Thomas Fischer; Andreas Hochhaus; Timothy Hughes; Klaus Lechner; Johan L Nielsen; Philippe Rousselot; Josy Reiffers; Giuseppe Saglio; John Shepherd; Bengt Simonsson; Alois Gratwohl; John M Goldman; Hagop Kantarjian; Kerry Taylor; Gregor Verhoef; Ann E Bolton; Renaud Capdeville; Brian J Druker
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245
  3 in total
  9 in total

Review 1.  Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review.

Authors:  Shruthi Harish Bindiganavile; Nita Bhat; Andrew G Lee; Dan S Gombos; Nagham Al-Zubidi
Journal:  J Immunother Precis Oncol       Date:  2021-02-25

Review 2.  Neuro-ophthalmic side effects of molecularly targeted cancer drugs.

Authors:  M T Bhatti; A K S Salama
Journal:  Eye (Lond)       Date:  2017-10-20       Impact factor: 3.775

3.  Optic disc edema as a possible complication of Imatinib mesylate (Gleevec).

Authors:  Soon-Il Kwon; Dae-Hyoung Lee; Yun-Jeong Kim
Journal:  Jpn J Ophthalmol       Date:  2008-09-05       Impact factor: 2.447

Review 4.  Ocular Toxicity of Targeted Anticancer Agents.

Authors:  Blake H Fortes; Prashant D Tailor; Lauren A Dalvin
Journal:  Drugs       Date:  2021-03-31       Impact factor: 9.546

5.  Optic neuropathy secondary to dasatinib in the treatment of a chronic myeloid leukemia case.

Authors:  Katia Sotelo Monge; Alberto Gálvez-Ruiz; Alberto Alvárez-Carrón; César Quijada; Anna Matheu
Journal:  Saudi J Ophthalmol       Date:  2015-01-06

Review 6.  Ocular side effects of biological agents in oncology: what should the clinician be aware of?

Authors:  Tobias Hager; B Seitz
Journal:  Onco Targets Ther       Date:  2013-12-24       Impact factor: 4.147

Review 7.  European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

Authors:  J L Steegmann; M Baccarani; M Breccia; L F Casado; V García-Gutiérrez; A Hochhaus; D-W Kim; T D Kim; H J Khoury; P Le Coutre; J Mayer; D Milojkovic; K Porkka; D Rea; G Rosti; S Saussele; R Hehlmann; R E Clark
Journal:  Leukemia       Date:  2016-04-28       Impact factor: 11.528

8.  Imatinib induces apoptosis by inhibiting PDGF- but not insulin-induced PI 3-kinase/Akt survival signaling in RGC-5 retinal ganglion cells.

Authors:  Swarajit K Biswas; Yan Zhao; Lakshman Sandirasegarane
Journal:  Mol Vis       Date:  2009-08-15       Impact factor: 2.367

Review 9.  Optic neuropathy in the context of leukemia or lymphoma: diagnostic approach to a neuro-oncologic emergency.

Authors:  Kenneth A Myers; Ana Nikolic; Kenneth Romanchuk; Ezekiel Weis; Marie-Anne Brundler; Lucie Lafay-Cousin; Fiona Costello
Journal:  Neurooncol Pract       Date:  2016-12-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.